

**18-JUN-2018 6:10
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
			REGS.	LAST Month	LAST Month	LAST Month	LAST DAYS	LAST DAYS	
S1007-Breast,Adj,N1,Endocrine+/-Chemo	1 Y 1	Recurrence Score testing	9383	204	0	0	0	0	BREAST
			9383	204	0	0	0	0	
	2 Y 2	Chemo and Endocrine Therapy	2547	76	0	0	0	0	
		3 Endocrine Therapy Alone	2536	78	0	0	0	0	
			5083	154	0	0	0	0	
S1207-Brst,Adj,Endocrine+/-Everolimus	1 Y 1	Blinded drug + Endocrine	808	181	91	46	12	1	BREAST
		2 Blinded drug + Endocrine	817	193	92	49	13	5	
			1625	374	183	95	25	6	
S1316-Compar. Effectiv. Trial for MBO	1 Y 1	Randomization Surgery	5	4	1	0	0	0	SURV
		2 Randomization Non-surgical M	5	4	0	0	0	0	
		3 Patient Choice Surgery	45	18	8	3	0	0	
		4 Patient Choice Non-surgical M	100	42	16	2	0	0	
			155	68	25	5	0	0	
S1415CD-TrACER CSF Standing Order Intervention for FN	1 Y 1	Site assigned to Cohort	500	279	138	80	20	4	CCD
		2 Site randomized: Control	332	241	91	44	16	3	
		3 SiteRand Int Risk: CSF	590	467	254	125	32	8	
		4 SiteRand Int Risk: No CSF	442	363	178	108	28	8	
			1864	1350	661	357	96	23	
S1417CD-Colorectal, Cost Cohort Study	1 Y 1	Observation	261	200	117	64	14	3	CCD
			261	200	117	64	14	3	
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	1 Y 1	Tissue for PD-L1 testing	242	207	119	62	17	6	BREAST
			242	207	119	62	17	6	
	2 Y 2	Observation	106	90	49	29	10	2	
		3 MK-3475 (Pembrolizumab)	102	86	53	24	11	1	
			208	176	102	53	21	3	
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol	1 Y 0	Screening	14	14	11	9	4	1	SURV
			14	14	11	9	4	1	
	2 Y 1	Carvedilol	2	2	1	0	0	0	
		2 No intervention	3	3	2	1	0	0	
		3 Observation	9	9	8	8	6	1	

**18-JUN-2018 6:10
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
				LAST Month	LAST Month	LAST Month	LAST DAYS	LAST DAYS	
			14	14	11	9	6	1	
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1 Y 1	TICE BCG	36	32	17	9	0	0	GU
		2 Tokyo-172 BCG	37	34	18	12	4	1	
		3 Prime + Tokyo-172 BCG	38	35	19	13	4	1	
			111	101	54	34	8	2	
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	0 Y 0	Pre-Registration	493	133	57	19	4	2	PREV
			493	133	57	19	4	2	
	1 Y 1	Blinded drug	61	19	12	5	1	0	
		2 Blinded drug	36	0	0	0	0	0	
		3 Blinded drug	35	0	0	0	0	0	
		4 Blinded drug	65	25	13	6	2	0	
			197	44	25	11	3	0	